InternationalUSRemember you can easily switch between MIP US and MIP International at any time

In-house roundup: US TERM Act is "blunt instrument"; SPC waiver prep begins; China patent amendment not enough; Insurtech filing surge to continue

Patrick Wingrove, London

Managing IP rounds up the latest news and analysis from in-house counsel in patent-focused businesses


US TERM bill is “blunt instrument” that would be disastrous say drug innovators 

Proposed legislation in the US House of Representatives seeks to limit patent term extension for pharmaceutical products in a way that pharma innovators say would stifle innovation and not solve potential drug pricing problems. Read More... 

SPC waiver: drug companies and patent offices start preparations 

With the EU SPC Manufacturing Waiver due to come into force next week, innovators, generics and patent offices say that they are looking at which products might be affected and whether to charge notification fees. Read more... 

Foreign businesses worried China’s Patent Law changes are too modest 

In-house counsel say they would have preferred to have seen more robust changes in the fourth amendment to China’s Patent Law as well as better predictability of rulings. Read more... 

Insurtech patent filings will grow as innovation becomes more important say insurance companies 

With insurtech patents increasing by 40% in 2017, in-house counsel at Allstate, The Hartford and elsewhere say filings will continue to go up as they seek to become more customer-centric organisations.


Most read articles

Latest Country Updates